Theravance Biopharma (TBPH) Profit After Tax (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Profit After Tax data on file, last reported at -$4.9 million in Q1 2026.

• On a quarterly basis, Profit After Tax rose 63.67% year-over-year to -$4.9 million in Q1 2026; TTM through Mar 2026 was $114.5 million, a 296.36% increase from a year earlier, with the FY2025 full-year figure at $105.9 million, up 287.7% from the prior year.
• Profit After Tax for Q1 2026 stood at -$4.9 million, down from $61.0 million in the prior quarter.
• Over the last five years, Profit After Tax for TBPH reached as high as $916.6 million in Q3 2022 and fell as low as -$41.5 million in Q1 2022.
• Historically, Profit After Tax has averaged $48.4 million across 5 years, with a median of -$12.7 million in 2024.
• Across the five-year window, Profit After Tax jumped 2696.1% in 2022 and tumbled 100.98% in 2023, its largest moves.
• Year by year, Profit After Tax stood at -$14.3 million in 2022, then surged by 40.31% to -$8.5 million in 2023, then slumped by 82.46% to -$15.5 million in 2024, then jumped by 493.02% to $61.0 million in 2025, then sank by 108.08% to -$4.9 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$4.9 million in Q1 2026, $61.0 million in Q4 2025, and $3.6 million in Q3 2025.